ea0016p304 | Endocrine tumours | ECE2008
Broecker-Preuss Martina
, Redmann Anja
, Britten Martin
, Mann Klaus
Objective: Therapeutic options for patients with dedifferentiated thyroid carcinoma are rare and alternative treatment strategies are needed. Among the most promising new agents for these patients are protein kinase inhibitors like the BRAF- and multi-targeted kinase inhibitor sorafenib. We have already shown that sorafenib inhibits growth of dedifferentiated thyroid carcinoma cell lines with and without BRAF mutation. The purpose of this study was to analyze the molecular eff...